Promoted Content
Promoted Content

Find Oncology Drugs in Phase I Clinical Development in FRANCE

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothThe 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group.

            Contact the Supplier

            Lead Product(s): W0180,Pembrolizumab

            Therapeutic Area: Oncology Product Name: W0180

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 09, 2020

            Details:

            W0180 is a first-in-class antibody targeting VISTA (V-domain Ig suppressor of T cell Activation). VISTA is a negative checkpoint regulator of T cell response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Valemetostat

            Therapeutic Area: Oncology Product Name: DS-3201

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 24, 2021

            Details:

            The partnership brings together Daiichi Sankyo, the Lymphoma Academic Research Organization, and the CALYM research alliance to perform clinical and translational research on valemetostat in patients with relapsed/refractory non-Hodgkin lymphoma.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TG4050

            Therapeutic Area: Oncology Product Name: TG4050

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: NEC Corporation

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 21, 2021

            Details:

            First patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. The vaccine is based on Transgene’s myvac® technology platform, which leverages cutting-edge AI capabilities to customize the treatment for each patient.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UCART22,Fludarabine Phosphate,Cyclophosphamide

            Therapeutic Area: Oncology Product Name: UCART22

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 05, 2020

            Details:

            UCART22 demonstrated preliminary signs of activity at low dose levels with fludarabine/cyclophosphamide (FC) lymphodepletion regimen, without unexpected nor significant treatment-related toxicities.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): UCARTCS1

            Therapeutic Area: Oncology Product Name: UCARTCS1

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            Cellectis worked closely with the FDA over the past months, to address the agency’s requests, which include adjustments to the MELANI-01 clinical protocol designed to enhance patient safety.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hafnium dioxide,Undisclosed

            Therapeutic Area: Oncology Product Name: NBTXR3

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            Details:

            NBTXR3 activated by radiation therapy produced a strong abscopal effect without a checkpoint inhibitor combination. NBTXR3 activated by radiation therapy stimulated adaptive antitumor immunity.